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1, INTRODUCTION 
The carbohydraze structure5 in glycolipids, 
glyco~r~teins and oljg~accha~des that GCKlftT A, 
B, H and Lewis Mood group ~~~~~~~~~~i~~ on thwz
moIt;cu~es are built np by s~~~~~~~~~ actian of a 
series of ~lycosyltransfer~es determined by genes 
at several different loci. The blood group genes at 
the ABO, H and Lewis loci are concerned only in 
the final stages of the biosynthesis of the car- 
bohydrate structures [11. The blood group A active 
SOlMAW% terminate with N-acetyl-D- 
galact,osamine in an ru-linkage to the C-3 position 
of a subterminal P-D-galactosyl unit which is also 
substituted at the C-2 position with L-fucose by the 
blood group H glycos~ltransferase. In these 
oligosaccharides the ~-D-g~actosyl residues may 
be joined ]I] by either a I-+ 3 (type f chain) or a 
1 ---+ 4 (type 2 chain) linkage to the following N- 
acetyl-D-glucosamine (table 1). 
The Lewis gene controls a glycosyltransferase 
which adds L-fucose on the 4 positian of the N- 
acetyl-D-glucosamine and therefore the Lea and 
Part of this work was presented at the 16th Congress of 
the International Society ttf Blood Transfusion in Mon- 
treal, August I980 
Leb active structures are based only on type I 
chains. The corresponding type 2 chain isomers 
have also been isolated but lack serologic Lea or 
Le” activity. The gene that controls a 
gly~sylira~sf~rase which adds L-fucose on the 3 
position of the ~-acetyl-D-glucosamine in these 
compounds appears to have a high frequency 
[2-4). One unique exception has however been 
described [S]. Carbohydrate determinants related 
to blood group A, but with two fucosyl substi- 
tuents, have been isolated from ovarial cyst 
glycoproteins and human urine oligosaccharides 
]6,7] and important data concerning their biosyn- 
thesis have been presented ]8,9]. Blood group A 
difucosyl hepta~lycosylceramides (glycoli~id) have 
been ~de~ti~ed and characterized from various 
sources IlO] and nothing is so far known about 
their biosynthesis. The aim of the present in- 
vestigation was to study the biosynthesis of these 
compounds, 
2. MATERIALS AND METHODS 
Serum was obtained from an AiRh( -) 
Le(a-b+) Fy(a-b-t) .Ik(a+b+) K(-) M(-) 
N( + ) S( - ) s( + ) P r( -F f secretor and concentrated 
4 times using a ‘Minicon’ concentrator at +-4OC. 
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Table 1 
Some carbohydrate chain endings of relevance to the text 
GalNAcal-+3Gal~1+3GlcNAc- 
2 
+ 
Fucal 
GalNAcal+3GalBl+4GlcNAc- 
2 
+ 
Fucal 
Gal61 + 3GlcNAc- 
4 
* 
Fucal 
Galfi1+4GlcNAc- 
3 
+ 
Fucal 
Gal61 + 3GlcNAc- 
2 4 
+ + 
Fucal Fucal 
GalB1+4GlcNAc- 
2 3 
+ + 
Fucal FucCil 
GalNAcal+3GalBl-+3GlcNAc- 
2 4 
+ + 
Fucal Fucal 
GalNAcal-+3Gal~1+451cNAc- 
2 3 
+ t 
Fucal FucCil 
Blood-group A determinant 
type 1 chain 
Blood-group A determinant 
type 2 chain 
Lea determinant 
type 1 chain 
‘X Jeterminant 
type 2 chain [23] 
Leb determinant 
type 1 chain 
Y determinant 
type 2 chain [23] 
Blood-group A, difucosyl 
determinant 
type 1 chain 
Blood-group A, difucosyl 
determinant 
type 2 chain 
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The concentrated serum sample was used im- tion of silicic acid chromatography and DEAE 
mediately or stored at -20°C before use. The chromatography essentially as described [ ii]. 
serum preparation was incubated under essentially The total non-acid glycosphingolipid fraction 
the same conditions as were described 141. The in- prepared from the incubation mixtures was analys- 
cubation mixture contained in a final volume of ed by thin-layer chromatography as native and 
100~1: 60 ~1 of the serum preparation, about acetylated derivatives. 
130000 cpm of GDP-[‘4C]fucose (Radiochemical Thin-layer chromatography was performed on 
Centre, Amersham), 2.5 pmol Tris-HCl buffer HPTLC plates (Merck). For autoradiographic 
(pH 79, 1 rmol NaN3, 0.75 pmol MgClz, 1 ymol detection Ilford 25GP X-ray film was used. After 
ATP, Triton X-100 0.1% and precursor glycolipid exposure the film was developed using Ilford 
50-2OOpg. The incubation mixture was kept at Phen-X, X-ray developer. Determination of 
37°C for 48 h under continuous gentle agitation. radioactivity was also done of an aliquot of the 
The incubation mixture was extracted sequen- fraction in a liquid scintillation spectrometer 
tially by 5 ml of methanol, chloroform/methanol (Packard) after evaporation of the organic solvent 
2: 1 v/v, chloroform/meth~ol 1:2 v/v and and addition of 10 ml of a solution containing 3 g 
methanol at 70°C. The combined extracts were PPO, 75 mg POPOP, 500 ml toluene and 250 ml 
evaporated to dryness and subjected to mild Triton X-100. For detection of non-radioactive 
alkaline hydrolysis and dialysis. Non-acid glycolipids the anisaldehyde reagent was used [ 121. 
glycosphingolipids were prepared by a combina- The blood group A active hexaglycosylceramide 
A B C 
A-6 GI A-7 Gl A-6 A-7 X A-7 GI A-6 X 
Fig. 1. Thin-layer chromatograms howing the non-acid glycosphingolipid fraction GP, prepared from an incubation 
mixture that contained a blood group A active hexaglycosyiceramide with a type 2 carbohydrate chain isolated from 
dog intestine, GDP-[‘4C]fucose and serum from an AIRh( -) Le(a - b +) secretor, analysed as native derivatives in two 
different solvents, fig.lA and B, and as acetylated derivatives in one solvent, fig. 1C. The precursor glycolipid, A-6 
(blood group A active hexaglycosylceramide with a type 2 chain), and the expected product, A-7 (blood group A similar 
difucosyl heptaglycosylceramide with a type 2 carbohydrate chain isolated from dog intestine) are also analysed as 
references. The solvent systems for the thin-layer plates were as follows: (A) chloroform/methanol/NH3 (cont.), 
40:40: 12, by voi.; (B) chloroform/methanol/water, 60:35:8, by vol.; (C) chloroform/methanol, 95:5, by vol. After 
development the thin-layer plates were covered with an X-ray film and left in the dark for 4 days. Lane X in A-C above 
shows the result of the autoradiographic detection of lane GP in each case. After autoradiography the plates were 
visualized with the anisaIdehyde reagent (121. 
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used as a precursor and the reference hep- 
taglycosylceramide were both isolated from dog in- 
testine and shown to have the following structures: 
GalNAccvl - 3Ga1(2 +-- lcvFuc)Pl + 
4GlcNAc@l- 3GaWl - 4Glc@l- 1Ceramide 
[13,14] and GalNAccvl -+ 3Ga1(2 +- lcvFuc)Pl 
- 4GlcNAc(3 - laFuc)Pl - 3Gal,&l ---+ 
4Glc@l ---+ 1Ceramide ([15,16] and McKibbin et 
al. unpublished). The ceramide composition was 
hydroxy fatty acids in combination with about 
equal amounts of the sphingosine basec t18:O and 
d18: 1. The ceramide composition was almost 
identical between the two glycolipids. 
3. RESULTS 
Figure IA-C show the thin-layer chromatogram 
of the non-acid glycosphingolipid fraction, GP, 
prepared from an incubation mixture that contain- 
ed a blood group A active hexaglycosylceramide 
with a type 2 carbohydrate chain isolated from dog 
intestine, GDP-[‘4C]fucose and serum from an 
ArRh( -) Le(a - b +) secretor, analysed as native 
derivatives in two different solvents, fig.lA and B, 
and as acetylated derivatives in one solvent, 
fig.lC. The precursor glycolipid, A-6 (blood group 
A active hexaglycosylceramide, type 2 chain), and 
the expected product, A-7 (the corresponding hep- 
taglycosylceramide with two fucose residues and a 
terminal hexosamine, type 2 chain), are also 
analysed as references. Lane X shows the 
autoradiographic detection of lane GP of the thin- 
layer plate. 
The non-acid glycosphingolipid fraction 
prepared after incubation, Gb, contained 2400 
counts/min (130000 cpm GDP-[‘4C]fucose was 
added initially). 
As can be seen the radioactive spot on the 
autoradiogram has the same Rr-value as the 
reference glycolipid, A-7, in all solvents used, both 
as native and as acetylated derivatives. 
4. DISCUSSION 
The preparation of a pure non-acid 
glycosphingolipid fraction from the incubation 
mixture is considered important for the interpreta- 
tion of results. An autoradiogram is obtainable at 
any preparative stage but the probability of a 
glycolipid causing the radioactive spot increases 
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with purity. This concept is not always 
appreciated. 
Identification of the product was based on com- 
parison of the thin-layer chromatographic mobility 
with a known reference of the expected product. 
The comparison was made both as native 
substances and as acetylated derivatives and using 
different solvent systems. Acetylation of 
glycosphingolipids has a profound effect on their 
chromatographic mobility and may also change 
the order between individual glycosphingolipids 
[17,18]. 
The ceramide composition of glycosphingolipids 
is also known to influence the chromatographic 
mobility. The partial separation into minor bands 
on the thin-layer plates, figs.lA-C, is most pro- 
bably caused by a heterogeneous ceramide as the 
carbohydrate part is uniform [13-161. It is 
therefore considered important to use reference 
compounds of similar ceramide compositions as 
the expected product for a safe identification based 
on thin-layer chromatographic mobility. In the 
present case both the precursor glycolipid and the 
reference glycolipid were prepared from the same 
source and shown to have almost identical 
ceramide composition [ 13- 161. 
Although no structural characterization (mass 
spectrometry, NMR, degradation) was done on the 
radioactive product, it appears safe to conclude the 
presence of an cul - 3 fucosyltransferase in the 
serum of a human A, Le(a - b + ) secretor (addi- 
tional typing, see above), capable of converting a 
blood group A active hexaglycosylceramide with a 
type 2 carbohydrate chain into the corresponding 
difucosyl compound under in vitro conditions, see 
fig.2. 
An alternative pathway would be from an Leb- 
similar hexaglycosylceramide with type 2 chain 
(table 1). However, a highly purified porcine blood 
group A specific N-acetylgalactosaminyl- 
transferase [9] failed to work on an Leb-active 
hexaglycosylceramide (type 1 chain). Unfortunate- 
ly, the type 2 chain isomer was not tested. 
The present knowledge about Fuccvl - 3 
transferase(s) is complex. Recently [19] Fuccvl - 
3 and Furl -+ 4 transferases were co-purified 
over 500000-fold from human milk, suggesting 
that both enzymatic activities reside in a single 
enzyme and thus obscuring the Lewis genetics (Le 
gene codes for a FUW1 - 4 transferase). Further- 
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GDP-14C-fucose 
Serum from an AIRh(-) Le(a-b+) secretor 
Mg 
2+ 
t 
A-6 (type 2 chain) 
GalNAcnl~3Gal~1~4G1cNAc~l~3Gal~l~4Glc~i~iCeramide 
2 3 
t t 
F&a F&xx 
Fig.2. Proposed biosynthetic scheme. 
more, evidence has been presented for the presence 
of two Fuccvl - 3 transferases in human saliva 
[20]. Both enzymes were shown capable of trans- 
ferring L-fucose to the C-3 position of N-acetyl-D- 
glucosamine while only one had capacity of trans- 
ferring L-fucose to C-3 of D-glucose and was fur- 
thermore dependent on the Le gene. If the enzyma- 
tic activity described in this paper is due to an ad- 
ditional enzyme species in a Fuml -+ 3 trans- 
ferase family or is due to a common Fuml -+ 3 
transferase with a limited precursor specificity re- 
quires further studies. 
The biosynthesized difucosyl heptaglycosyl- 
ceramide (type 2 chain) has so far not been found 
on red blood cell membranes [21]. Its type 1 chain 
isomer, the Siedler antigen, has however been 
shown to be taken up on red cells from plasma 
[22]. The sire for its biosynthesis is unknown. The 
biological importance of the described Fuc~~l - 
3 enzymatic activity remains to be elucidated. 
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